Skip to main content

and
  1. Article

    Open Access

    Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer

    Adjuvant immune checkpoint blockade (ICB) following chemoradiotherapy and adding ICB to chemotherapy have been key advances for stages III-IV non-small cell lung cancer (NSCLC) treatment. However, known biomar...

    Yinjie Gao, Michelle M. Stein, Matthew Kase in Cancer Immunology, Immunotherapy (2023)